Re: Novavax (NVAX): Un Nuevo Comienzo
redplate:
Yes excellent speculation they ((GSK-my note)) are one of the top three in flu and the only real potential competitor I RSV. They are indeed the most likely suitor. Not a sure thing but likely. Personally I like them a lot as they bought out my company for 1.6B @ 31.50/share. All cash. They see themselves as THE vaccine pharma and want RSV all to themselves. It is their pathway to being the top selling vaccine company.
--
Most experts predict that maternal immunization for RSV is a 1-1.5B dollar market. Elderly RSV is a 2B dollar market. All together it is 3B or so. Just saying real world